Achieve Life Sciences

Achieve Life Sciences(ACHV)

SEATTLE, WA
Biotechnology1 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules

Achieve Life Sciences is a life sciences company focused on Small Molecules.

OncologyNephrology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Cytisinicline
Smoking Cessation
Phase 1
Clinical Trials (1)
NCT05566288Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers
Phase 1
OGX-427
Neoplasms
Phase 1
Clinical Trials (1)
NCT00487786Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT03268343A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine
Phase 1
cytisinicline
Renal Impairment
Phase 1
Clinical Trials (1)
NCT05631938Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose
Phase 1
SN2310 Injectable Emulsion
Breast Neoplasms
Phase 1
Clinical Trials (1)
NCT00385177Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT03509948A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation
Phase 1
Phase 1
Clinical Trials (1)
NCT03848208A Single Dose-escalation Study of Cytisine in Adult Smokers
Phase 1
Phase 1
Cytisinicline
Smoking Cessation
Phase 1
Clinical Trials (1)
NCT05981768Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers
Phase 1
Custirsen, paclitaxel and carboplatin
Cancer
Phase 1
Phase 1/2
Clinical Trials (1)
NCT03303911A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT00138658A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2
S-8184 Paclitaxel Injectable Emulsion
Carcinoma, Non-Small-Cell Lung
Phase 2
Clinical Trials (1)
NCT00034164Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer
Phase 2
Phase 2
Clinical Trials (1)
NCT00096668Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer
Phase 2
Phase 2
Clinical Trials (1)
NCT02423590Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers
Phase 2
Phase 2
Clinical Trials (1)
NCT01120470OGX-427 in Castration Resistant Prostate Cancer Patients
Phase 2
Phase 2
Clinical Trials (1)
NCT01681433OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
Phase 2
TOCOSOL Paclitaxel
Bladder Neoplasms
Phase 2
Clinical Trials (1)
NCT00077688TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
Phase 2
OGX-427 600 mg
Urologic Neoplasms
Phase 2
Clinical Trials (1)
NCT01454089A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Phase 2
Phase 2
Clinical Trials (1)
NCT01829113Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
Phase 2
Phase 2
Clinical Trials (1)
NCT03709823Trial of Cytisine in Adult Smokers
Phase 2
S-8184 Paclitaxel Injectable Emulsion
Colorectal Adenocarcinoma
Phase 2
Clinical Trials (1)
NCT00034190Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma
Phase 2
Phase 2
Clinical Trials (1)
NCT01844817Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
Phase 2
S-8184 Paclitaxel Injectable Emulsion
Ovarian Cancer
Phase 2
Clinical Trials (1)
NCT00034151Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer
Phase 2
S-8184 Paclitaxel Injectable Emulsion
Urologic Neoplasms
Phase 2
Clinical Trials (1)
NCT00034177Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium
Phase 2
Phase 2
Clinical Trials (1)
NCT01780545Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Phase 2
Phase 2
Clinical Trials (1)
NCT00327340Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
Phase 2
cytisinicline
Vaping
Phase 2
Clinical Trials (1)
NCT05431387A Study of Cytisinicline for Vaping Cessation in Adult Smokers
Phase 2
Phase 3
Clinical Trials (1)
NCT00251095Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
Phase 3
cabazitaxel
Prostate Cancer
Phase 3
Clinical Trials (1)
NCT01578655Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Phase 3
Phase 3
Cytisinicline
Smoking Cessation
Phase 3
Clinical Trials (1)
NCT04576949A Study of Cytisinicline for Smoking Cessation in Adult Smokers
Phase 3
Phase 3
Cytisinicline
Vaping Cessation
Phase 3
Clinical Trials (1)
NCT07392125Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes
Phase 3
Cytisinicline
Smoking Cessation
Phase 3
Clinical Trials (1)
NCT05206370A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers
Phase 3
Phase 3
Clinical Trials (1)
NCT01630733A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Phase 3
Cytisinicline
Smoking Cessation
Phase 3
Clinical Trials (1)
NCT06435221Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 33 clinical trials
H-1B (2023): 1 approval
SEC Filings: 2 available

Financials (FY2024)

R&D Spend
$30M26%
Net Income
-$42M
Cash
$16M
Source: SEC 10-K Filing

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub